Zhejiang Jolly PharmaceuticalLTD Balance Sheet Health
Financial Health criteria checks 6/6
Zhejiang Jolly PharmaceuticalLTD has a total shareholder equity of CN¥2.6B and total debt of CN¥381.6M, which brings its debt-to-equity ratio to 14.4%. Its total assets and total liabilities are CN¥3.9B and CN¥1.2B respectively. Zhejiang Jolly PharmaceuticalLTD's EBIT is CN¥592.6M making its interest coverage ratio -58.9. It has cash and short-term investments of CN¥786.3M.
Key information
14.4%
Debt to equity ratio
CN¥381.56m
Debt
| Interest coverage ratio | -58.9x |
| Cash | CN¥786.31m |
| Equity | CN¥2.64b |
| Total liabilities | CN¥1.23b |
| Total assets | CN¥3.87b |
Recent financial health updates
Recent updates
Does Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Deserve A Spot On Your Watchlist?
Nov 28
Investors Still Aren't Entirely Convinced By Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Earnings Despite 32% Price Jump
Oct 17These 4 Measures Indicate That Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Is Using Debt Safely
Oct 06It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
Aug 30We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease
Jul 29Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%
May 13A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)
May 08There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings
Mar 01Financial Position Analysis
Short Term Liabilities: 300181's short term assets (CN¥2.3B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 300181's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥57.1M).
Debt to Equity History and Analysis
Debt Level: 300181 has more cash than its total debt.
Reducing Debt: 300181's debt to equity ratio has reduced from 27.8% to 14.4% over the past 5 years.
Debt Coverage: 300181's debt is well covered by operating cash flow (73%).
Interest Coverage: 300181 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 12:08 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Jolly Pharmaceutical Co.,LTD is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |
| Suqing Huang | Everbright Securities Co. Ltd. |